FDA sends Reata back to the drawing board
The need for another pivotal trial of omaveloxolone in Friedreich's ataxia looks increasingly likely.
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Five questions for Astrazeneca on its Covid-19 vaccine
Outstanding issues include whether Astra can file AZD1222 in the US, and why a lower priming dose seemed to produce the best efficacy.
Medtech
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Company Events
Go or no go? The year ends with Covid-19 vaccine approvals in sight
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Novartis’s big wager on RNAi approaches the finish line
The Covid-19 pandemic might yet delay US approval of Novartis's cholesterol-lowering project Leqvio − and then come the commercial questions.
Go or no go? Big decisions loom for Bristol and Sanofi
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.
Interviews
Astra aims for “the Trump setting”
Pivotal trials of Astrazeneca's Covid-19 antibody get under way, with hopes that a longer half-life and more convenient dosing will set the project apart.
The other kind of Covid-19 immunity
As antibody tests pile up, Oxford Immunotec is working on an assay to detect T cell responses to the coronavirus.
Novo adds weight to its obesity goals
Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.